TGFBI Human
Transforming Growth Factor Beta Induced Human Recombinant
Cat. No.
BT15782
Source
Escherichia Coli.
Synonyms
Transforming growth factor-beta-induced protein ig-h3, Beta ig-h3, Kerato-epithelin, RGD-containing collagen-associated protein, RGD-CAP, TGFBI, BIGH3, CSD, CDB1, CDG2, CSD1, CSD2, CSD3, EBMD, LCD1, CDGG1.
Appearance
Sterile filtered liquid formulation.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Usage
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs 
In Stock 
Description
TGFBI Human Recombinant produced in e.Coli is a single, non-glycosylated, polypeptide containing 135 amino acids (502-636) and having a molecular mass of 14.5 kDa.
The TGFBI recombinant Human protein is purified by proprietary chromatographic techniques.
Product Specs
Introduction
Transforming Growth Factor Beta Induced protein, also known as TGFBI, is an extracellular matrix protein induced by transforming growth factor beta 1 (TGF-β1). This protein plays a crucial role in various cellular processes, including cell growth and differentiation, wound healing, and cell adhesion. Notably, certain missense mutations in the TGFBI gene have been linked to autosomal dominant corneal dystrophies in humans. The TGFBI gene encodes a protein consisting of 683 amino acids, characterized by an RGD motif and four internal repeating domains. These domains, known as Fasciclin domains, exhibit highly conserved sequences across different species.
Description
Recombinant Human TGFBI, produced in E. coli, is a non-glycosylated polypeptide chain comprising 135 amino acids (spanning positions 502-636). With a molecular weight of 14.5 kDa, this protein variant is purified using proprietary chromatographic techniques.
Physical Appearance
Sterile, filtered liquid solution.
Formulation
The recombinant Human TGFBI is supplied in a 20mM Tris-HCl buffer with a pH of 8.
Stability
For short-term storage (2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to freeze the product at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is advisable for long-term storage. Repeated freezing and thawing should be avoided.
Purity
The purity of the product exceeds 95.0%, as determined by SDS-PAGE analysis.
Synonyms
Transforming growth factor-beta-induced protein ig-h3, Beta ig-h3, Kerato-epithelin, RGD-containing collagen-associated protein, RGD-CAP, TGFBI, BIGH3, CSD, CDB1, CDG2, CSD1, CSD2, CSD3, EBMD, LCD1, CDGG1.
Source
Escherichia Coli.
Amino Acid Sequence
MGTVMDVLKG DNRFSMLVAA IQSAGLTETL NREGVYTVFA PTNEAFRALP PRERSRLLGD AKELANILKY HIGDEILVSG GIGALVRLKS LQGDKLEVSL KNNVVSVNKE PVAEPDIMAT NGVVHVITNV LQPPA.
Product Science Overview
Introduction
Transforming Growth Factor Beta Induced (TGFBI), also known as βig-H3 or keratoepithelin, is an extracellular matrix protein induced by Transforming Growth Factor Beta (TGF-β). It plays a crucial role in various physiological and pathological processes, including cell growth, differentiation, apoptosis, and extracellular matrix production .
Discovery and Nomenclature
Structure and Function
TGFBI is a secreted protein that interacts with various components of the extracellular matrix. It contains four fasciclin-1 (FAS1) domains, which are involved in cell adhesion and interaction with integrins. TGFBI is known to bind to integrins such as α3β1, αvβ3, and αvβ5, mediating cell adhesion and migration .
Biological Roles
TGFBI has diverse biological functions, including:
- Cell Adhesion and Migration: TGFBI promotes cell adhesion and migration by interacting with integrins and other extracellular matrix components .
- Tumor Suppression and Promotion: TGFBI has dual roles in cancer. It can act as a tumor suppressor by inducing apoptosis in cancer cells. However, it can also promote tumor progression by enhancing cell motility, invasion, and adhesion, depending on the tumor microenvironment .
- Wound Healing: TGFBI is involved in wound healing processes by promoting cell migration and extracellular matrix production .
- Corneal Dystrophy: Mutations in the TGFBI gene are associated with various forms of corneal dystrophy, a group of genetic eye disorders that affect the transparency of the cornea .
Clinical Implications
TGFBI has significant clinical implications in various diseases:
- Cancer: TGFBI expression is often altered in cancers. Loss of TGFBI expression has been observed in several cancers, including ovarian cancer, where it acts as a tumor suppressor. Conversely, high levels of TGFBI can promote metastasis in certain cancers .
- Corneal Dystrophy: Mutations in TGFBI are linked to corneal dystrophies such as granular corneal dystrophy and lattice corneal dystrophy. These conditions lead to the accumulation of abnormal protein deposits in the cornea, affecting vision .
- Fibrosis: TGFBI is involved in fibrotic processes, where excessive extracellular matrix production leads to tissue scarring and organ dysfunction .
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
